NASDAQ:IDXX - IDEXX Laboratories Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$243.00 +0.98 (+0.40 %)
(As of 09/21/2018 11:25 AM ET)
Previous Close$243.21
Today's Range$242.26 - $244.10
52-Week Range$146.09 - $256.22
Volume3,826 shs
Average Volume429,831 shs
Market Capitalization$20.86 billion
P/E Ratio74.02
Dividend YieldN/A
Beta0.64
IDEXX Laboratories logoIDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300

Debt

Debt-to-Equity Ratio-14.77
Current Ratio0.96
Quick Ratio0.73

Price-To-Earnings

Trailing P/E Ratio74.02
Forward P/E Ratio58.13
P/E Growth2.2

Sales & Book Value

Annual Sales$1.97 billion
Price / Sales10.69
Cash Flow$4.3634 per share
Price / Cash55.69
Book Value($0.62) per share
Price / Book-391.94

Profitability

EPS (Most Recent Fiscal Year)$3.28
Net Income$263.14 million
Net Margins14.50%
Return on Equity-703.80%
Return on Assets21.21%

Miscellaneous

Employees7,600
Outstanding Shares86,590,000
Market Cap$20.86 billion

IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories announced that its Board of Directors has authorized a stock buyback program on Sunday, June 4th 2017, which authorizes the company to buyback 3,000,000 outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company's board of directors believes its stock is undervalued.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its quarterly earnings results on Wednesday, August, 1st. The company reported $1.23 EPS for the quarter, beating the Zacks' consensus estimate of $1.17 by $0.06. The company had revenue of $580.75 million for the quarter, compared to analyst estimates of $574.68 million. IDEXX Laboratories had a net margin of 14.50% and a negative return on equity of 703.80%. The company's revenue for the quarter was up 14.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.87 earnings per share. View IDEXX Laboratories' Earnings History.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for IDEXX Laboratories.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY18 earnings guidance on Wednesday, August, 1st. The company provided earnings per share (EPS) guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus estimate of $4.15. The company issued revenue guidance of $2.205-2.23 billion, compared to the consensus revenue estimate of $2.23 billion.

What price target have analysts set for IDXX?

6 analysts have issued twelve-month price objectives for IDEXX Laboratories' shares. Their forecasts range from $215.00 to $260.00. On average, they expect IDEXX Laboratories' stock price to reach $238.00 in the next year. This suggests that the stock has a possible downside of 2.1%. View Analyst Price Targets for IDEXX Laboratories.

What is the consensus analysts' recommendation for IDEXX Laboratories?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

Who are some of IDEXX Laboratories' key competitors?

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the folowing people:
  • Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 62)
  • Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 56)
  • Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Sec. (Age 59)
  • Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 54)
  • Mr. Jay Mazelsky, Exec. VP (Age 57)

Has IDEXX Laboratories been receiving favorable news coverage?

News articles about IDXX stock have trended somewhat positive recently, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. IDEXX Laboratories earned a news and rumor sentiment score of 0.18 on Accern's scale. They also gave media stories about the company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for IDEXX Laboratories.

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.25%), Fundsmith Equity Fund L.P. (5.12%), Renaissance Technologies LLC (2.51%), Bank of New York Mellon Corp (1.28%), Bank of New York Mellon Corp (1.28%) and Northern Trust Corp (1.19%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Lawrence D Kingsley, Michael Lane, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Which institutional investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Columbus Circle Investors, Wells Fargo & Company MN, Bank of America Corp DE, Janus Henderson Group PLC, FMR LLC, Federated Investors Inc. PA and TCW Group Inc.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Michael Lane and William T End. View Insider Buying and Selling for IDEXX Laboratories.

Which institutional investors are buying IDEXX Laboratories stock?

IDXX stock was acquired by a variety of institutional investors in the last quarter, including Fundsmith Equity Fund L.P., Marshall Wace LLP, Ardevora Asset Management LLP, Worldquant Millennium Quantitative Strategies LLC, CIBC Private Wealth Group LLC, First Trust Advisors LP, Renaissance Technologies LLC and Baird Financial Group Inc.. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $243.00.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $20.86 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. IDEXX Laboratories employs 7,600 workers across the globe.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]


MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  373 (Vote Outperform)
Underperform Votes:  235 (Vote Underperform)
Total Votes:  608
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel